Sunday, 15 June 2014

Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar Safety and Efficacy Profile to Lantus

For the first time today, Eli Lilly and Boehringer Ingelheim Pharmaceuticals Inc. presented data showing that LY2963016, the alliance's investigational new insulin glargine product, has a similar safety and efficacy profile to currently marketed insulin glargine (Lantus®)


Lilly's Once-Weekly Dulaglutide Shows Similar Reductions in Average Blood Glucose Levels as Once-Daily Liraglutide in Head-to-Head Trial

Once-Weekly Dulaglutide 1.5 mg Also Demonstrates Weight Loss, Low Rates of Hypoglycemia in AWARD-6 Trial (Lilly)

No comments:

Post a Comment